Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study

Author:

Coates Laura C.1ORCID,McInnes Iain B.2ORCID,Merola Joseph F.3,Warren Richard B.4,Kavanaugh Arthur5,Gottlieb Alice B.6,Gossec Laure7ORCID,Assudani Deepak8,Bajracharya Rajan8,Coarse Jason9,Ink Barbara8,Ritchlin Christopher T.10ORCID

Affiliation:

1. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, University of Oxford and Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust Oxford UK

2. University of Glasgow Glasgow UK

3. Harvard Medical School, Brigham and Women's Hospital Boston Massachusetts

4. Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre The University of Manchester Manchester UK

5. Division of Rheumatology, Allergy, and Immunology UC San Diego School of Medicine La Jolla California

6. Department of Dermatology The Icahn School of Medicine at Mount Sinai New York New York

7. Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Rheumatology Department Pitié‐Salpêtrière Hospital, AP‐HP Paris France

8. UCB Pharma Slough UK

9. UCB Pharma Raleigh North Carolina

10. Department of Medicine University of Rochester New York New York

Funder

UCB Pharma

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3